Genmab Announces Approval of DARZALEX (daratumumab) in Frontline Multiple Myeloma in Japan
August 22, 2019 at 7:10 AM CEST
Company Announcement
- DARZALEX??approved in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant in Japan
- Genmab to receive USD 7 million milestone payment
- Approval based on data from Phase III ALCYONE study
Attachment